Developing new treatments and vaccines has been crucial to returning to a new normal. The life science industry’s success at identifying candidate treatments and vaccines, and demonstrating their safety and efficacy, is why many parts of the world are now able to relax restrictions.
Post-pandemic, the value of drug discovery has been understood by the wider public, and in 2022, the world is watching the health and life sciences sector more than ever before. Testing and research continues in earnest across the globe and the sector meets the challenge of increased expectations to produce better results faster. The pressure is on for labs across the country.
However, lab managers face significant challenges, and are required to operate under significant and increasing strain. There’s one issue they face, which while ultimately unavoidable, hugely contributes to drug discovery labs’ challenge: downtime.
Downtime is a perennial problem for those working across all types of industries, whether in laboratories or manufacturing plants. For example, the pandemic forced a huge number of businesses to halt their operations, whether it was to contain the spread of the coronavirus, due to supply issues or due to staff absences.